MorphoSys AG
Lena-Christ-Strasse 48
Martinsried
Munich
82152
Germany
Tel: 49-0-89-899-27-0
Fax: 49-0-89-899-27-222
Website: http://www.morphosys.com/
Email: info@morphosys.com
560 articles about MorphoSys AG
-
MorphoSys AG Reports First Nine Months and Third Quarter 2021 Results
11/11/2021
"Monjuvi sales continued to build momentum in the third quarter where we saw a broadening of the prescriber base and increased utilization in second-line patients," said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.
-
MorphoSys Announces Departure of Roland Wandeler
11/9/2021
MorphoSys AG announced that Roland Wandeler, Ph.D., has decided to step down from his position as Chief Operating Officer and member of the MorphoSys Management Board effective December 31, 2021 to pursue other opportunities.
-
MorphoSys to Present MANIFEST and RE-MIND2 Data from Expanded Hematology-Oncology Portfolio at the 2021 American Society of Hematology (ASH) Annual Meeting
11/4/2021
MorphoSys AG announced that new data on approved and clinical-stage therapeutics will be presented during the American Society of Hematology Annual Meeting from December 11-14 in Atlanta, Georgia United States.
-
MorphoSys Presents Interim Results from M-PLACE Study with Felzartamab during American Society of Nephrology Annual Meeting
11/4/2021
MorphoSys AG presented interim results from the M-PLACE study with felzartamab at the 2021 Annual Meeting of the American Society of Nephrology (ASN) on November 4-7.
-
MorphoSys AG Announces Monjuvi(R) Sales for the First Nine Months and Third Quarter of 2021 and Invitation to the Upcoming Conference Call on November 11, 2021
11/2/2021
MorphoSys AG today announces that revenues from product sales of Monjuvi (R) (tafasitamab-cxix) in the U.S. amount to 18.6 million (US$ 22 million) for the third quarter of 2021 and 46.4 million (US$ 55.5 million) for the first nine months of 2021.
-
MorphoSys AG: First Patient Dosed in Phase 2 IGNAZ Study of Felzartamab in Patients with Immunoglobulin A Nephropathy
10/20/2021
MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the first patient has been dosed in the Phase 2 IGNAZ clinical trial evaluating felzartamab for patients with Immunoglobulin A Nephropathy (IgAN).
-
MorphoSys' Licensing Partner Roche Received Breakthrough Therapy Designation for Gantenerumab in Alzheimer's Disease
10/11/2021
MorphoSys AG announced that its licensing partner Roche received Breakthrough Therapy Designation by the U.S. Food and Drug Administration for gantenerumab, an anti-amyloid beta antibody developed for subcutaneous administration, for the treatment of people living with Alzheimer's disease.
-
Incyte and MorphoSys Announce the European Commission Approval of Minjuvi® (tafasitamab) in Combination With Lenalidomide for the Treatment of Adults With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
8/26/2021
Incyte (Nasdaq:INCY) and MorphoSys AG (FSE:MOR; NASDAQ:MOR) today announced that the European Commission (EC) has granted conditional marketing authorization for Minjuvi® (tafasitamab) in combination with lenalidomide.
-
MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
8/26/2021
MorphoSys AG and Incyte announced that the European Commission has granted conditional marketing authorization for Minjuvi® in combination with lenalidomide, followed by Minjuvi monotherapy, for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplant.
-
MorphoSys' Partner Incyte Announced Development and Commercialization Agreement with InnoCare for Tafasitamab in Greater China
8/17/2021
MorphoSys AG announced that Incyte, its development and commercialization partner for tafasitamab, entered into a collaboration and license agreement with a subsidiary of InnoCare for tafasitamab in Greater China.
-
BeiGene is building a new research and development and manufacturing facility on a 42-acre campus in New Jersey, while MorphoSys is now growing its presence in the greater Boston area.
-
MorphoSys AG Reports Second Quarter and First Half 2021 Results
7/29/2021
We regained the momentum in Monjuvi sales as we exited the second quarter and are encouraged to see that momentum continuing into Q3," said Jean-Paul Kress, M.D., Chief Executive Officer of MorphoSys.
-
MorphoSys AG to Update Financial Guidance for 2021 and Reduce Financial Liabilities
7/26/2021
MorphoSys AG announces an update of its financial guidance for 2021 after preliminary completion of the latest evaluation of MorphoSys' half year 2021 financial performance.
-
The life sciences is always a frenetic sector when it comes to mergers & acquisitions, initial public offerings (IPOs) and Series A announcements (not to mention B and C rounds). But during the second quarter of 2021, these companies were especially busy bees – all positive signs that the industr...
-
Invitation to MorphoSys' Second Quarter and First Half 2021 Results Conference Call on July 29, 2021
7/21/2021
MorphoSys AG, a commercial-stage biopharmaceutical company and a leader in antibody and protein technologies, will publish its results for the second quarter and first half 2021 on July 28, 2021 at 10:00pm CEST.
-
MorphoSys Concludes a US $100 Million Capital Increase to Implement the Purchase of 1,337,552 shares by Royalty Pharma
7/16/2021
MorphoSys AG ; announced that its Management Board, with the approval of the Supervisory Board, has passed a resolution to increase the share capital of MorphoSys AG by issuing 1,337,552 new ordinary shares from the Authorized Capital 2021-II, excluding pre-emptive rights of existing shareholders, to implement the purchase of 1,337,552 new ordinary shares by Royalty Pharma Investments 2019 ICAV, a subsidiary of Royalty Pharma plc .
-
MorphoSys to Complete Transformational Acquisition of Constellation Pharmaceuticals, Bolstering Its Position in Hematology-Oncology
7/15/2021
MorphoSys AG announced the successful completion of its previously announced cash tender offer for all outstanding shares of Constellation Pharmaceuticals, Inc. for $34.00 per share, net to the seller in cash, without interest and subject to any applicable withholding of taxes.
-
MorphoSys Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Constellation Pharmaceuticals
7/1/2021
MorphoSys AG today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended for its tender offer for Constellation Pharmaceuticals, Inc.
-
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
6/25/2021
Incyte and MorphoSys Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
-
MorphoSys and Incyte Announce Positive CHMP Opinion for Tafasitamab in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
6/25/2021
If approved, tafasitamab in combination with lenalidomide would represent an important new therapeutic option for eligible DLBCL patients in the European Union